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ABSTRACT 
 
 
INTRODUCTION 
 
      Human immunodeficiency virus is a retrovirus that affects all 
systems in the body.Among this cardiovascular disease is one of the leading 
causes of non HIV related death in HIV patients. 
   Although many cardiovascular complications have been 
described like pulmonary hypertension, systemic hypertension, infective 
endocarditis and accelerated atherosclerosis  in HIV patients,the most 
common complications include diastolic dysfunction, left ventricular 
systolic dysfunction ,pericardial  effusion, dilated cardiomyopathy and 
coronary artery disease.  
                  As the disease progresses the CD4 count  declines  which 
increases the cardiovascular complications leading to death. So 
echocardiographic screening should be performed in all HIV patients with 
low CD4 count for early detection and management of the complications. 
AIMS AND OBJECTIVES 
1.To assess the cardiac abnormalities such as systlolic dysfunction, diastolic 
dysfunction, dilated cardiomyopathy, coronary artery disease, pulmonary 
hypertension and infective endocarditis and their correlation with CD4 
count. 
2.To evaluate whether this parameter can be used as prognostic marker of 
disease progression in HIV patients  
MATERIALS AND METHODS 
STUDY POPULATION :  
                This study was conducted among 200 HIV positive patients 
coming to ART centre, Govt.Rajaji Hospital, Madurai.  
 STUDY PROTOCOL 
               Cases  were  classified  as HIV patients into four groups  
depending upon the CD4 cell count >500 ( stage1),CD4 cell count 200 – 500 
(stage 2), and  50-200(stage 3) and <50 (stage 4). CD4 count, ECG and 
Echocardiograrm were done in all the participants of the study. 
RESULTS   
              In this study pericardial effusion was the most common finding and 
was present in 15% of the study population, followed by systolic 
dysfunction(13%),diastolic dysfunction (11.5%) and dilated cardiomyopathy 
(9%) and all were statistically significant.All cardiac abnormalities were 
present in patients in stage 3&4 with low CD4 count (<200/microlitre)  
 
CONCLUSION  
           Cardiovascular  abnormalities  are  more common and predictable       
complications in  late stages  of HIV infection.So all HIV patients with low 
CD4 count(<200/microlitre) should be screened for cardiac 
abnormalities.Early diagnosis and management of  these complications is 
associated with increased survival rates and clinical outcomes in HIV 
patients. 
  
 
 
 
 
                              INTRODUCTION 
Human immunodeficiency virus is a retrovirus that affects all systems 
in the body.Among this cardiovascular disease is one of the leading causes of 
non HIV related death in HIV patients. Risk factors for cardiovascular 
disease in HIV patients include traditional risk factors, chronic inflammation 
associated with HIV infection and metabolic effects of antiretroviral therapy. 
HIV infection itself is a independent risk factor for cardiovascular diseases. 
 HIV infection increases the production of various cytokines which are 
toxic to myocytes and thereby increases the risk of cardiovascular 
complications. HIV infection induced endothelial dysfunction and vasculitis 
are also playing an important role in pathogenesis of these complications. 
 Although  many cardiovascular complications have been described like 
pulmonary hypertension, systemic hypertension, infective endocarditis and 
accelerated atherosclerosis  in HIV patients,the most common complications 
include diastolic dysfunction, left ventricular systolic dysfunction ,pericardial  
effusion, dilated cardiomyopathy and coronary artery disease. Rapid onset 
congestive heart failure leads to death in HIV patients within 6 to 12 months 
of diagnosis. 
 As the disease progresses the CD4 count  declines  which increases the 
cardiovascular complications leading to death. So echocardiographic 
  
 
 
 
 
screening should be performed in all HIV patients with low CD4 count for 
early detection and management of the complications. 
 This study was conducted to study the prevalence of cardiac 
complications in HIV patients and their correlation with CD4 count. 
 
 
 
                              
 
 
 
 
 
 
                        
                           
 
  
 
 
 
 
                        AIMS AND OBJECTIVES 
 
1. To assess the cardiac abnormalities such as systlolic dysfunction, 
diastolic dysfunction, dilated cardiomyopathy, coronary artery disease, 
pulmonary hypertension and infective endocarditis and their 
correlation with CD4 count. 
 
2. To evaluate whether this parameter can be used as prognostic marker 
of disease progression in HIV patients.   
 
 
 
 
              
 
 
                
  
 
 
 
 
                          REVIEW OF LITERATURE 
 HISTORY AND PROBLEM STATEMENT 
                  AIDS(Acquired immunodeficiency  syndrome), recognised as an 
emerging disease in early 1980s and has evolved from a mysterious illness to 
a global pandemic which has infected tens of million in less than twenty 
years. In 1981, AIDS was recognised in US and  HIV virus was isolated from 
a patient with lymphadenopathy and it was determined that HIV was the 
causative agent for AIDS.  
                In the year 2007, it was estimated that around 33 million people are 
living with HIV in the world. And 2.4 million people are living with HIV in 
India.  
           According to estimates by World health organisation at the end of 
2013, 35 million people were living with HIV and around 11.7 million people 
had access to antiretroviral therapy in low and middle income countries. Over 
28  million people are eligible for antiretroviral therapy, under WHO. 
 
 
                        
                      
  
 
 
 
 
                       TYPES OF HIV EPIDEMICS 
 WHO and UNAIDS define the different types of HIV epidemics as follows. 
 
Low level 
epidemics 
HIV prevalence has not consistently exceeded more 
than 5% in any defined subpopulation 
Concentrated 
epidemics 
HIV prevalence has  consistently exceeded more than 
5% in atleast one subpopulation but < 1% in pregnant 
women. 
Generalised HIV in 
epidemics 
HIV prevalence has consistently exceeded more than 
5% in any defined subpopulation and > 1% in pregnant 
women. 
         
     
 
 
  
 
  
 
 
 
 
HIV PREVALENCE STATEMENT IN (SEAR) COUNTRIES,2007  
 
COUNTRY ESTIMATED NUMBER 
OF PLHA 
PERCENTAGE OF ADULT 
POPULATION INFECTED  
WITH  HIV 
BANGLADESH 12,000 <0.1% 
BHUTAN <500 <0.1% 
INDIA 24,00,000   0.3% 
INDONESIA 2,70,000   0.2% 
MALDIVES <100   0.1% 
MYANMAR 2,40,000   0.7% 
NEPAL 70,000   0.5% 
SRILANKA 3,800  <0.1% 
THAILAND 6,10,000   1.4 
                     
                                 
 
  
 
 
 
 
                    HIV PREVALENCE IN INDIA 
Based on the sentinel surveilliance  data,HIV prevalence classified into three 
groups. 
GROUP I – HIGH PREVALENCE STATES 
                    >5% in high risk groups and 1% or > 1% in pregnant women 
                    -Tamilnadu, Maharastra, Karnataka,  
                    -Andhrapradesh, Manipur, Nagaland. 
GROUP II - MODERATE PREVALENCE STATES 
                     >5% in high risk groups and <1% in pregnant women 
                    - Gujarat,Goa, Pondicherry. 
GROUP III -  LOW PREVALENCE STATES 
<5% in high risk groups and <1% in pregnant women                 
-Remaining states. 
 
 
 
 
  
 
 
 
 
                   DEFINITION AND CLASSIFICATION 
            The current CDC(Center for disease control and prevention) classified 
the HIV infected person based on clinical condition and CD4 cell count . 
            HIV patient  is said to have AIDS when the CD4 count 
<200/microlitre irrespective of presence of signs, symptoms and 
opportunistic infections. 
 
CD4+ T cell 
count (per µL) 
Category A – 
asymptomatic/ 
acute HIV/ PGL 
Category B – 
symptomatic  
Category C – 
AIDS indicators 
>500 A1 B1 C1 
200 – 400 A2 B2 C2 
<200 A3 B3 C3 
 
 
 
  
 
 
 
 
CATEGORY A : consists of  patients with one or more  of  the  following 
conditions , but conditions enumerated under category B or C must not have 
occurred. These include : 
Asymptomatic HIV infection 
Generalised lymphadenopathy (present persistently) 
Acute HIV infection with associated  illness or history of acute HIV 
infection. 
 
CATEGORY B:  consists of patients with one or more of  the following  
conditions, but those under category C must not have occurred plus  the 
condition is related to HIV or defect in cell mediated immunity. These 
include[11] :       
 Bacillary angiomatosis 
 Oral thrush 
 Vulvovaginal candidiasis  recurrent/ non responsive to treatment 
 Cervical dysplasia/ carcinoma in situ 
 Fever/ diarrhoea > 1 month 
 Oral hairy leukoplakia 
  
 
 
 
 
 >1 episode/ >1 dermatome – Herpes zoster 
 Idiopathic thrombocytopenic purpura 
 Listeria infection 
 PID like tubo ovarian abscess 
 Peripheral neuropathy 
 
Category c-AIDS defining illness 
 Invasive candidiasis (esophagus, trachea, lung or bronchi) 
 Invasive cervical malignancy 
 Coccidioidomycosis 
 Cryptococcosis  
  Chronic intestinal Cryptosporidiosis / Isospora infection 
 CMV retinitis 
 HIV encephalopathy 
 Herpes simplex infections ( bronchitis, pneumonia, esophagitis) 
 Histoplasmosis  
 Kaposi sarcoma 
 Primary CNS lymphoma 
 Burkitt’s  lymphoma 
  
 
 
 
 
 Pulmonary or extrapulmonary TB 
 Mycobacterium Avium Complex infection 
 Pneumocystis carinii pneumonia 
 Progressive multifocal leukoencephalopathy (PML) 
 CNS toxoplasmosis 
 AIDS cachexia 
 Recurrent pneumonia/ Salmonella sepsis 
 
 
 
 
 
 
 
 
                        
 
  
 
 
 
 
                          HIV VIRUS 
           HIV virus is classified under the family of retroviridae and 
subfamily of lentivirus.Two subtypes of HIV virus have been identified. HIV 
1 is the most common subtype in worldwide.HIV virus is easily killed by 
heat and it is readily  inactivated  by either,acetone,ethanol 20% and  
betapropionolactone. It is relatively resistant to ionizing radiation and UV 
light 
                                    MORPHOLOGY 
Spherical in shape and enveloped virus 
90-120nm in size  
Genome contains two identical single strandard +one RNA copy and Reverse 
transcriptase   
Three structural genes –gag,pol and env 
 Non-structural and regulatory genes  
                                 tat,nef,rev,vif,vpu,vpr. 
 
 
                          
  
 
 
 
 
                  STRUCTURE OF THE HIV VIRUS 
 
.  
 
                      
  
 
 
 
 
                    MAJOR ANTIGENS OF HIV 
A. Envelope  antigens  -   1.spike antigen –gp120 
                                       2.transmembrane pedicle Ag-gp41 
B. Shell antigen -             Nucleocapsid protein p18  
C. core antigens 
    1.principal core antigen p24 
    2.other core antigens-p15,p55 
D. Polymembrane antigens-p31,p51,p66 
 
GENE FUNCTION 
gag  Core of virion (incuding p24 antigen) 
pol   Protease, reverse transcriptase and integrase enzymes 
Env Envelope glycoproteins 
tat, rev, nef, vif, vpr, 
vpu  
Regulates viral gene replication and host cell 
modification to enhance viral growth 
 
  
 
 
 
 
                          GROUPS 
 4 groups - group M (major), group O (outlier),group N and group P 
 Group M  is further subclassified into subtypes.  Includes  9 subtypes : 
A, B, C, D, F, G, H, J and K 
 Sometimes patients are infected with more than one subtype which 
recombine to give rise to CRFs (circulating recombinant forms). 
Examples include , CRF01_AE  and  CRF02_AG 
 Subtype A and F are further sub classified into sub – sub – types such 
as A1, A2 and F1, F2. 
 The geographic distribution of these different strains is widely 
distributed.A, B, C, D, G and CRF01_AE,CRF_AG  are by far the 
common strains globally.While subtype C is the most prevalent strain. 
 There are numerous implications to this genetic diversity such as : 
     1. Wide diversity (subtypes, circulating recombinant forms) 
 2. Continuous viral evolution 
 3. Different rates of disease progression 
 4. Varied response to therapy &  
    5.Development of  resistance 
    6. Inability to develop vaccine against wide range of strains   
  
 
 
 
 
GEOGRAPHIC DISTRIBUTION OF HIV &SUBTYPES 
1. Sub-Saharan Africa Subtype C (most common) 
Subtype B and G,    CRFO2_AG 
2. India Subtype C 
3. China Subtypes B, C and  
BC recombinant forms 
3. Southeast Asia CRF01_AE 
4. North America and some 
parts of South America 
Subtype B 
5. Australia Subtype B 
6. Western Europe Subtype B 
7. Eastern Europe  Subtype A,B and  
AB recombinant forms 
New emerging strains: 
Thai B.   Indian C. southern China* 
CRF03_AB  Former soviet union 
CRF14_BG  Spain*   Portugal*  
BF recombinant forms South America  
CRF35_AD  Afghanistan and Iran* 
 
  
 
 
 
 
          GEOGRAPHIC DISTRIBUTION OF HIV &SUBTYPES 
 
 
 
  
 
 
 
 
                                 REPLICATION  CYCLE  
                     HIV virus enters into the body through blood or tissues of 
infected person. After entering the virus binds with host cell (CD4 
lymphocyte) by using the envelope antigens  gp120  and gp41.Binding of 
HIV to the host cell can also be mediated by the HIV coreceptors CXCR4(for 
Tcell trophic HIV strains) and CCR5(for macrophage trophic strains). 
                    After the fusion of HIV with the host cell membrane HIV 
genome is uncoated and internalised into the cell.Then the virus reverse 
transcriptase mediates the transcription of HIV RNA into double strandard 
DNA which is incorporated into the host cell genome which leads to 
formation of proviruses.  
                    
                         
  
 
 
 
 
                   TRANSMISSION  OF HIV        
HIV can be transmitted through sexual,blood and blood products   and 
maternal-fetal transmission. 
 SEXUAL TRANSMISSION 
 Can be through homosexual or heterosexual route 
 Male to female transmission rate is higher than female to male 
transmission rate .Increased risk of heterosexual transmission in the 
presence of genital ulcer. 
 
        
 
 
  
 
 
 
 
 Unprotected receptive anal intercourse increased the rate of           
transmission because of thin fragile rectal mucous membrane. 
 Oral sex is associated with decreased risk of HIV transmission     
compare to vaginal and anal sex . 
 Uncircumcised males are more prone to develop HIV infection       
because of the foreskin contains plenty of langerhan cells , CD4 T 
cells and macrophages which are the targets of HIV 
 
TRANSMISSION BY BLOOD AND BLOOD PRODUCTS 
             The first case of HIV infection transmitted through the blood 
products was reported in 1982. HIV virus can be transmitted by transfusion 
of contaminated white blood cells, platelets and clotting factors. 
             Transfusion of hyperimmune gammaglobulin ,hepatitisB Ig,HepB 
vaccine and Rh Ig will not transmit the infection.Any skin piercing including  
injection ,ear pricking,tattoing and acupuncture can also transmit the 
infection.  
 
 
 
  
 
 
 
 
MOTHER TO FETUS/INFANT  TRANSMISSION 
 Maternal  to fetus transmission occurs  during pregnancy,during 
delivery and by breast feeding  
 Low maternal CD4 count is associated with high rate of transmission 
 Prolonged second stage of labour also increase the risk of HIV 
transmission  
                        In the absence of prophylactic ART to the mother during 
pregnancy, risk of mother to fetus transmission is around 10% to 25% in 
industrialised countries, 20% to 25% in developing countries.With 
prophylactic ART, rate of transmission decreases by 5%. 
   Graph showing the number of perinatally acquired cases in children  
 
  
 
 
 
 
TRANSMISSION BY OTHER BODY FLUIDS 
 Saliva contains so many antiviral factors such as IgA , IgG And IGM   
mucins , thrombospondin 1, secretory lecukocyte  protease 
inhibitor(SLPI)  which inhibits the replication of HIV and increases the 
clearance by the host. 
 Transmission of HIV by human bite is very rare.  
 Exposure to body fluids such as sweat, urine and tears will not transmit 
the HIV infection 
                  
                      MODES OF HIV TRANSMISSION 
SEXUAL ROUTE   87% 
MOTHER TO CHILD  5% 
BLOOD AND BLOOD 
PRODUCTS 
2% 
INJECTION DRUG USE 2% 
UNKNOWN 4% 
                                 
 
  
 
 
 
 
 CLINICAL FEATURES OF HIV INFECTION  
                 AIDS ( Acquired immuno deficiency syndrome) is a fatal illness 
characterised by multisystem involvement and development of various 
opportunistic infections leading to death 
Clinical manifestation of HIV infection have been classified into 3 broad 
categories 
1. Acute HIV syndrome 
2. Asymptomatic stage  
3. Symptomatic disease 
ACUTE HIV SYNDROME 
                    Around 50% to 70% of the individuals will develop acute HIV 
infection after 3 to 6 weeks of primary infection. Most common 
manifestations include fever, pharyngitis, headache, nausea, vomiting and 
diarrhoea. Symptoms will persist for several weeks and gradually subside. 
Neurology and dermatologic manifestations also occur in acute HIV 
syndrome 
Systemic symptoms:  
         Cutaneous manifestations 1.Mucocutaneous ulcer  
                                                   2.Erythematous maculopapular rash 
  
 
 
 
 
Fever Pharyngitis 
Myalgia Arthralgia 
Weight loss Nausea 
Vomiting Diarrhea 
Headache Retro orbital pain 
Lymphadenopathy  
 
Neurological manifestations: 
Encephalitis Aseptic meningitis 
Acute transverse myelitis Peripheral neuropathy  
Acute demyelinating Encephalomyelitis   
 
 
Approximately around 10% of HIV patients will have fulminant course even 
after the disappearance of signs and symptoms. 
If antiretroviral therapy (ART) is initiated during the acute HIV infection, 
small percentage of patients may revert to a negative ELISA test. But after 
discontinuation of the treatment rapidly they will reseroconvert to positive 
test. 
  
 
 
 
 
 
                        ASYMPTOMATIC STAGE 
During the asymptomatic stage antibodies to HIV is present in the serum but 
no signs and symptomps of the disease. Duration of the asymptomatic stage 
varies from months to years.During this period rate of fall of CD4 count is 
50/microlitre/year.  
 
             SYMPTOMATIC DISEASE 
During the course of illness, signs and symptoms appear at any stage of 
illness.Symptoms depends upon the rate of fall of CD4 count.As the CD4 
count decreases,opportunistic infection increases leading to fatal 
complications. 
  
 
 
 
 
 
 
    NATURAL HISTORY OF THE DISEASE IN HIV INFECTION  
 
  
 
 
 
 
RESPIRATORY SYSTEM  INVOLVEMENT         
                   Most common manifestation of pulmonary disease is pneumonia. 
HIV patients have six fold increase in incidence of  pneumococcal 
pneumonia.Pneumocysti carini pneumonia occurs in patients with CD4 count 
<200/microlitre.Classical chest xray finding is dense perihilar infiltrate which  
is unusual in HIV patients. 
                 Mycobacterium avium complex infection is seen in patients with 
CD4 count<50/microlitre.Fungal infections can also cause pneumonia in HIV 
patients. Two forms of Idiopathic pneumonia(Lymphoid interstitial 
pneumonia &Nonspecific interstitial pneumonia) have been recognized and 
are seen in 1% of  adult HIV patients.It is due to polyclonal activation of 
lymphocytes.Transbronchial biopsy is diagnostic in 50% of cases and the 
disease is usually self limited. 
               Sinus infection is also common in HIV patients .Maxillary sinus is 
most commonly involved.Common organisms causing sinusitis in HIV 
infection are H.influenza and Staph aureus. Fungal infection like 
mucormycosis in HIV infection progresses very slowly and responds to 
amphotericinB 
 
 
  
 
 
 
 
DISEASE OF OROPHARYNX AND GIT 
             Gastrointestinal manifestations in HIV infections are most commonly 
due to secondary infections , Kaposi sarcomas, and lymphomas. And they 
occur in patients with CD 4 count <300 /micro litre. Most common oral 
infections include thrush,hairy leukoplakia and aphthous ulcers.  
             Oesophagitis in HIV is due to Candida,CMV,HSV Infections. HSV 
ulcers are usually multiple while CMV ulcer is usually solitary. Achlorhydria 
is also common in HIV infection but other gastric problems are rare. 
           Diarrheal illness in HIV is caused by bacterial infections like 
Salmonella, Shigella and Campylobacter spp, fungal infections like 
Penicillosis , Histoplasmosis,Coccididomycosis,and Parasitic infections such 
as Cryptosporidia,Microspora &Isospora belli.  
           CMV colitis was one of the common manifestations in pre ART  era, 
but after the introduction of ART its incidence have been decreased. Patients 
with gastro intestinal manifestations should be screened for ophthalmic 
evaluation for CMV retinitis. 
                        Some patients with HIV infections may develop a chronic 
diarrheal syndrome called AIDS or HIV enteropathy for which no cause other 
than HIV infection can be identified. Rectal lesions due to reactivation of 
herpes simplex are also more common in HIV infection.    
  
 
 
 
 
DISEASES OF KIDNEY & GENITOURINARY SYSTEM 
              Diseases of genitourinary system are due to direct consequences of 
HIV infection or due to neoplasm or opportunistic infections or drug 
toxicities. HIV associated nephropathy (HIVAN) can be an early 
manifestation of HIV infection. Proteinuria is the most common finding in 
this disorder. Renal biopsy is diagnostic of HIVAN.  
             Drug causing renal toxicities in HIV infection are Amphotericin, 
pentamidine,adefovir,cidofovir and foscarnet. Renal stones are caused by 
Indinavir in 10% of cases.Condylomata lata  a form of secondary syphilis 
most commonly seen in HIV patients. 
            Vulvovaginal candidiasis is common problem in females with HIV 
infections and symptoms include pruritus and dysuria. Microscopic 
examination of vaginal discharge for psuedohyphae in 10% KOH. 
Fluconazole is used in treatment of severe form of disease. 
RHEUMATOLOGIC & IMMUNOLOGICAL DISEASES :  
               Drug allergies are the most common significant allergic reactions 
occurring in around 65% of patients receiving Trimethoprim-
Sulphamethoxazole for pneumocystitis carnii pneumonia. 
  
 
 
 
 
              Anaphylaxis in HIV  is usually rare due to ART except Abacavir 
which can cause fatal allergic reactions. HLA B-57 strongly associated with 
allergic reactions due to abacavir. 
              The one auto immune disease that occur in increased frequency in 
HIV Infections is a variant of Primary Sjogren’s syndrome in which salivary 
gland is infiltrated with CD8 T cells. In Sjogren’s syndrome  CD4  T cell 
infiltrates are more prominent.  
            Reactive arthritis also occurs in one third of HIV patients and well 
responds to standard therapy. HIV or AIDS associated arthropathy is 
characterised by sub acute oligo arthritis developing over a period of over 
one to six weeks and lasting for six weeks to six months. It usually involves 
large joints.  
             Another type of arthritis also called as painful articular syndrome 
which involves the large joints and affects 10% of AIDS patients, presenting 
as a acute severe sharp pain in the affected joint. It affects primarily the 
knee,elbow & ankle joints and lasts for 2-24 hours. 
         In very few patients some rare clinical manifestations like 
leucocytoclastic vasculitis, CNS angiitis and polymyositis have been 
reported.  
 
  
 
 
 
 
DERMATOLOGICAL MANIFESTATIONS: 
                    Dermatological manifestations occurs in around 10% of HIV  
patients .It will vary from simple skin rash to cutaneous malignancies. The 
most common non neoplastic problems are seborrheic dermatitis, folliculitis 
and opportunistic infections .  
                        Seborrheic dermatitis occurs in around 50% OF HIV  patients    
and   causative organism is Pityrosporum ovale.Folliculitis is the next most 
prevalent dermatological abnormalities seen in 20% of HIV  patients. 
                       Reactivation of Herpes zoster is seen in 10 -20% of HIV  
patients. This reactivation syndrome of varicella-zoster virus indicates a 
modest decline in immune function and may be the first indication of clinical 
immunodeficiency.. The clinical manifestations of reactivation zoster in HIV-
infected patients, although indicative of immunologic compromise, are not as 
severe as those seen in other immunodeficient conditions.  
                  Thus, while lesions may extend over several dermatomes, involve 
the spinal cord, and/or be associated with frank cutaneous dissemination, 
visceral involvement has not been reported. In contrast to patients without a 
known underlying immunodeficiency state, patients with HIV infection tend 
to  have  recurrences of zoster with a relapse rate of 20%.Valacyclovir, 
acyclovir or famciclovir is the treatment of choice. Foscarnet may be of value 
  
 
 
 
 
in patients with acyclovir-resistant virus. Infections with HSV is associated 
with recurrent oro labial genital and peri anal lesions as a part of recurrent 
reactivation syndrome.  
Allergic reactions like steven johnson syndrome, toxic epidermal 
necrolysis can occur in HIV infections due to sulpha drugs and abacavir and 
protease inhibitor like ambrenavir, darunavir, fosamprenavir and tipranavir. 
Zidovudine therapy is associated with elongation of the eye lashes and bluish 
discoloration of the nails and they are  more common in American and 
African patients.  
           Other rare cutaneous problems include eosinophilic pustular 
folliculitis, icthyosis and  psoriasis.  
 
 
 
 
 
 
 
  
 
 
 
 
HEPATOBILIARY MANIFESTATIONS. 
                 HCV infection is  more common  and 10 fold increase of death in 
HIV infection when compared to general population.Granulomatous hepatitis 
is one of the worst complication seen in HIV patients and the causative 
organisms are mycobacterium avium complex and fungal infections. 
            Hepatic mass also caused by tuberculosis,pertussis,hepatitis or 
fungal infections like C.immitis  and H.capsulatum may be seen  and  in HIV 
patients.Nucleoside reverse transcriptors also cause hepatitis which is 
fulminant in some patients.Indinavir can also cause hyperbilirubinemia. 
           Pentamidine and didanosine are the important causes of pancreatitis 
in HIV patients.Biliary tract disease-papillary stenosis and sclerosing 
cholangitis have also been reported in HIV patients. 
DISEASES OF ENDOCRINE SYSTEM AND METABOLIC DISORDERS 
            HIV lipodystrophy is a common metabolic problem in patients 
receiving Antiretro viral therapy and develops in 30-75% of patients.It can 
develop anytime from 6 weeks to several years after initiation of ART.  
 
 
 
  
 
 
 
 
Characteristic features of lipodystrophy are 
 Increased total cholesterol, 
 Increased triglycerides,        
 Increased apolipoprotein B, 
 Hyperinsulinemia, 
 Hyperglycemia and 
 Fat redistribution -truncal obesity&peripheral wasting. 
             Next to lipodystrophy the other common metabolic abnormality in 
HIV patients is hyponatremia .The important causes include syndrome of 
inappropriate antidiuretic hormone secretion (SIADH)due to pulmonary and 
CNS lesion,due to adrenal gland involvement by HIV infection itself and by 
CMV,cryptococcosis and histoplasmosis and due to drug toxicity by 
Antiretroviral therapy. 
          Thyroid gland is most common gland involved in HIV infection and 
the most common abnormality is subclinical hypothyroidism.Grave’s disease 
can also occur 9 to 48 months after initiation of HAART. 
          Around 50% of HIV patients develops hypogonadism and erectile 
dysfunction.Testicular dysfunction can also be due to ganciclovir therapy. 
Avascular necrosis of hip and shoulder,osteoporosis have also been 
developed in HIV infection. 
  
 
 
 
 
DISEASE OF HEMATOPOIETIC SYSTEM  
                 Hematolgical  abnormalities seen in HIV infection include 
anemia,leukopenia,thrombocytopenia which may be due to HIV infection, 
nutritional, drug induced, secondary infections and neoplasms.Zidovudine 
and dapsone are two drugs  most commonly associated with anemia.   
                In some patients generalised lymphadenopathy may be the first 
presentation.Monoclonal gammapathy of unknown significance(MGUS) 
have been reported in 3% of HIV infection. 
            Thrombocytopenia in HIV infection may be due to associated HCV 
infection, cirrhosis  and thrombotic thrombocytopenic purpura. Incidence of 
venous thromboembolism in HIV infection is 1% per year. Causes of bone 
marrow suppression in HIV patients include  infections like mycobacterium , 
fungus, parvovirus B19 and lymphomas and drugs like zidovudine, dapsone, 
ganciclovir , interferon alpha, trimethoprim sulfmethoxazole , pyrimethamine 
and foscarnet  
               The incidence of venous thromboembolic disease such as deep-vein 
thrombosis or pulmonary embolus is approximately 1% per year in patients 
with HIV infection. This is approximately 10 times higher than that seen in 
an age-matched population. 
  
 
 
 
 
             Among the factors associated with clinical thrombosis are age over 
45, history of an opportunistic infection, lower CD4 count, and estrogen use. 
Abnormalities of the coagulation cascade including decreased protein S 
activity, increase in factor VIII, anticardiolipin antibodies, or lupus-like 
anticoagulant have been reported in more than 50% of patients with HIV 
infection. The clinical significance of this increased propensity toward 
thromboembolic disease is likely reflected in the observation that elevations 
in d-dimer are strongly associated with all-cause mortality in patients with 
HIV infection. 
OCULAR MANIFESTATIONS(50%) 
               Ocular manifestations occur in 50% of patients in late stage of HIV 
infection.Cotton wool spots are the most common fundus finding and these 
are due to retinal ischemia. 
           CMV retinitis is one of the dangerous  ophthalmic complication of 
HIV infection and occurs in patients with CD4 count <100/microlitre.So all 
patients with  CD4 count <100/microlitre ophthalmic screening for CMV 
retinitis should be done. 
          Acute retinal necrosis syndrome or progressive outer retinal necrosis is 
a rapidly progressing bilateral necrotizing retinitis and the patient may 
present with keratitis and iritis.It is most often associated with HSV or 
  
 
 
 
 
varicella infection.Syphilitic uveitis and  kaposi sarcoma of eyelids and 
conjunctiva are rarely seen in HIV infection. 
NEUROLOGICAL MANIFESTATIONS 
           Neurological problems in HIV infection is due to  direct consequence  
of  the virus or  secondary to opportunistic infections like toxoplasmosis 
,cryptococcosis,CMV infection or mycobacterial infection. 
                   Cryptococci neoformans  is the most common  cause of 
meningitis in HIV infection cccurs in patients with CD4 count less than 
100/microlitre.Diagnosis is confirmed by identification of organism in CSF  
by Indian ink examination. 
                   HIV associated dementia may be initial AIDS defining illness in 
3% of cases.Around 25% of patients with HIV infection will develop 
clinically significant encephalopathy in late stages  of HIV infection and it 
progresses slowly over months.It should be diagnosed after ruling out the 
other causes of encephalopathy.A major feature of this entity is the 
development of dementia, defined as a decline in cognitive ability from a 
previous level. It may present as impaired ability to concentrate, increased 
forgetfulness, difficulty in reading, or increased difficulty in performing 
complex tasks. Initially these symptoms may be indistinguishable from 
findings of situational depression or fatigue.  
  
 
 
 
 
                In contrast to "cortical" dementia (such as Alzheimer's disease), 
aphasia, apraxia, and agnosia are uncommon, leading some investigators to 
classify HIV encephalopathy as a "subcortical dementia" characterized by 
defects in short-term memory and executive function. 
               In addition to dementia, patients with HIV encephalopathy may also 
have motor and behavioral abnormalities. Among the motor problems are 
unsteady gait, poor balance, tremor, and difficulty with rapid alternating 
movements. Increased tone and deep tendon reflexes may be found in 
patients with spinal cord involvement. Late stages may be complicated by 
bowel and/or bladder incontinence. 
              Behavioral problems include apathy, irritability, and lack of 
initiative, with progression to a vegetative state in some instances. Some 
patients develop a state of agitation or mild mania. These changes usually 
occur without significant changes in level of alertness. This is in contrast to 
the finding of somnolence in patients with dementia due to toxic/metabolic 
encephalopathies 
     The precise cause of HIV-associated dementia remains 
unclear,although the condition is thought to be a result of a combination of 
direct effects of HIV on the CNS and associated immune activation.           
         Multinucleated giant cells, macrophages, and microglial cells 
appear to be the main cell types harbouring virus in the CNS. Histologically, 
  
 
 
 
 
the major changes are seen in the subcortical areas of the brain and include 
pallor and gliosis, multinucleated giant cell encephalitis, and vacuolar 
myelopathy. Less commonly, diffuse or focal spongiform changes occur in 
the white matter. Areas of the brain involved in motor, language, and 
judgment are most severely affected. 
      Combination antiretroviral therapy is of benefit in patients with 
HIV-associated dementia. Improvement in neuropsychiatric test scores has 
been noted for both adult and pediatric patients treated with antiretrovirals. 
The rapid improvement in cognitive function noted with the initiation of 
cART suggests that at least some component of this problem is quickly 
reversible, again supporting at least a partial role of soluble mediators in the 
pathogenesis. It should also be noted that these patients have an increased 
sensitivity to the side effects of neuroleptic drugs. The use of these drugs for 
symptomatic treatment is associated with an increased risk of extrapyramidal 
side effects.Therefore, patients with HIV encephalopathy who receive these 
agents must be monitored carefully. 
         
             Seizures may be initial manifestion in some patients with HIV 
infection. The seizure threshold is often lower in patients with advanced HIV 
infection due to the presence of electrolyte abnormalities. 
 
  
 
 
 
 
Causes of Seizures in Patients with HIV Infection 
 
 HIV encephalopathy 
 Cerebral toxoplasmosis 
 Cryptococcal meningitis 
 Primary central nervous system lymphoma 
 Progressive multifocal leukoencephalopathy 
 
 
              Spinal cord disease is seen in 20% of patients with HIV 
infection.Three main types of spinal cord disease are vacuolar myelopathy,  
pure sensory ataxia,&paresthesia/dysesthesia. Other neurological 
manifestations present in HIV infection are progressive multifocal 
leukoencephalopathy, primary CNS lymphoma,kaposi sarcoma,aseptic 
meningitis, peripheral neuropathy(AIDP&CIDP) and myopathy.  
 
 
 
 
 
  
 
 
 
 
WASTING SYNDROME IN HIV INFECTION 
                    Generalised wasting is an AIDS-defining condition; it is defined 
as involuntary weight loss of >10% associated with intermittent or constant 
fever and chronic diarrhea or fatigue lasting >30 days in the absence of a 
defined cause other than rarely seen today with the earlier initiation of 
antiretrovirals.  
                 A constant feature of this syndrome is severe muscle wasting with 
scattered myofiber degeneration and occasional evidence of myositis. 
Glucocorticoids may be of some benefit; however, this approach must be 
carefully weighed against the risk of compounding the immunodeficiency of 
HIV infection. Androgenic steroids, growth hormone, and total parenteral 
nutrition have been used as therapeutic interventions with variable success. 
  
 
 
 
 
 
  
 
 
 
 
IMMUNE  RECONSTITUTION INFLAMMATORY SYNDROME  
                       In some patients following inititation of ART , paradoxical 
worsening of preexisting , untreated or partially treated opportunistic 
infections occur due to Type 4 hypersensitive reactions. This is known as 
immune  reconstitution inflammatory syndrome (IRIS). Signs and symptoms 
may appear at any time from two weeks to two years after initiation of ART 
and the symptoms include fever, localised lymphadenitis, pulmonary 
infiltrates, uveitis, sarcoidosis, grave’s disease and raised ICT. It can be fatal 
in few patients and steroids can be used in treatment of IRIS.  
CHARACTERISTICS OF IRIS 
 Paradoxical worsening of the clinical condition following initiation of 
ART. 
 Occurs weeks to months following initiation of ART. 
 Most common in patients starting therapy with CD4 count 
<50/microlitre 
 Frequently seen in patients with tuberculosis. 
 Can be fatal. 
 
 
  
 
 
 
 
OPPORTUNISTIC  INFECTIONS IN HIV INFECTION IN RELATION  
TO CD4 COUNT 
 
CD4 Count < 500 / microlitre : 
 Bacterial infections like TB,Herpes simplex 
 Herpes Zoster,Vaginal Candidiasis 
 Hairy leukoplakia,Kaposi sarcoma 
CD4 Count <200 / microlitre : 
 Pneumocystosis,Toxoplasmosis 
 Coccidiomycosis,Cryptosporidiosis 
CD4 Count < 50 / microlitre : 
o Disseminated MAC infection,Histoplasmosis 
o CMV Retinitis,CNS Lymphoma 
 
 
 
 
  
 
 
 
 
LABORATORY DIAGNOSIS OF HIV INFECTION 
                                  Diagnosis of  HIV infection based on demonstration of 
antibodies to virus or direct demonstration of HIV or one of its components 
.Antibodies to HIV in the blood appears generally 3-12 weeks of infection . 
 
ELISA(ENZYME LINKED IMMUNOSORBENT ASSAY) TEST  
                 It is the best screening test for HIV infection.This test is also 
known as enzyme immunoassay.Results of this test is graded as 
positive(highly reactive), intermediate (partially reactive) and negative 
(nonreactive). 
                   If results are intermediate it should be repeated within 4-6 wks 
ELISA test is positive usually within 22 days of infection. 
 
 
  
 
 
 
 
WESTERN BLOT TEST 
                This is a highly specific test for detection of HIV infection.It is 
based on detection of specific antibody to viral core protein p24 and envelope 
glycoprotein p41. Results of this test is also graded as positive(highly 
reactive),intermediate (partially reactive) and negative (nonreactive). If 
results are intermediate it should be repeated within 4-6 weeks 
 
 
 
                     WESTERN BLOT TEST 
 
 
 
  
 
 
 
 
TESTS FOR DIRECT DETECION OF HIV COMPONENTS  
                Following  laboratory  tests  are used for direct detection of HIV 
and its components. 
          1.p24 capture assay-Positive in 50% of patients; detects  
 down to 15 pg/mL of p24 protein 
          2.HIV RNA detection by PCR- Reliable to 40 copies/mL of  
           HIV RNA  
3. HIV RNA detection by  bDNA- Reliable to 50 copies/mL    
       of HIV RNA 
4.HIV RNA detection by NASBA(Nucleic Acid Sequence 
Based Amplification)- Reliable to 80 copies/mL of HIV RNA 
 
  TESTS FOR MONITORING OF PATIENTS WITH HIV INFECTION 
1.CD4  T cell count  
2.HIV RNA estimation  
3.Complete blood count  
4.HIV resistance testing  
5.Co-receptor tropism arrays. 
6.Beta2 microglobulin                                      
     
  
 
 
 
 
 PRINCIPLES OF MANAGEMENT OF HIV INFECTION 
                 Various guidelines  have been described in the management of 
HIV infection.Treatment plan should be based on plasma CD4 count and 
HIV RNA level.Main goal of treatment should be aimed at suppression of 
viral replication. 
                   Most effective therapy for HIV infection is combination ART.All 
pregnant women should be treated with ART to reduce to  the materno-fetal 
transmission.cART will not cure the disease,but prolong the life and quality  
of HIV patients.  
1. Ongoing HIV replication leads to immune system damage and progression 
to AIDS. 
2. Plasma HIV RNA levels indicate the magnitude of HIV replication and the 
rate of CD4+ T cell destruction. CD4+ T cell counts indicate the current level 
of competence of the immune system. 
3. Rates of disease progression differ among individuals, and treatment 
decisions should be individualized based on plasma HIV RNA levels and 
CD4+ T cell counts. 
4. Maximal suppression of viral replication is a goal of therapy; the greater 
the suppression the less likely the appearance of drug-resistant quasispecies. 
  
 
 
 
 
5. The most effective therapeutic strategies involve the simultaneous 
initiation of combinations of effective anti-HIV drugs with which the patient 
has not been previously treated and that are not cross-resistant with 
antiretroviral agents that the patient has already received. 
6. The antiretroviral drugs used in combination regimens should be used 
according to optimum schedules and dosages. 
7. The number of available drugs is limited. Any decisions on antiretroviral 
therapy have a long-term impact on future options for the patient. 
8. Women should receive optimal antiretroviral therapy regardless of 
pregnancy status. 
9.Compliance is an important part of ensuring maximal effect from a given 
regimen. The simpler the regimen, the easier it is for the patient to be 
compliant. 
 
 
 
 
 
 
  
 
 
 
 
 INITIAL EVALUATION OF PATIENT WITH HIV INFECTION  
 History&Physical examination  
  Complete hemogram 
 Liver and renal function tests 
 Blood sugar&Lipid profile 
 CD4 count  
 HIV RNA level 
 Screening for Hepatitis A,B&C,syphilis&tuberculosis 
 Pretest counseling 
INDICATIONS FOR INITIATION FOR ANTIRETROVIRAL  
THERAPY        
  1.Acute infection syndrome 
  2. Chronic infection 
A. Symptomatic disease (including HIV-associated         
    nephropathy) 
B. Asymptomatic disease 1. CD4+ T cell count <500/  
                                          2. Pregnancy 
  3. Postexposure prophylaxis 
 
 
 
  
 
 
 
 
INDICATIONS FOR CHANGING ANTIRETROVIRAL THERAPY 
 
 Less than a 10 fold reduction  in plasma HIV RNA by 4 weeks 
following the initiation of therapy 
 A reproducible significant increase (defined as threefold  
greater)    from the nadir of plasma HIV RNA level not 
attributable to intercurrent infection, vaccination, or test 
methodology 
 Persistently declining CD4+ T cell numbers 
 Clinical deterioation&Side effect 
POSTEXPOSURE PROPHYLAXIS  
                Postexposure prophylaxis is a necessary secondary 
preventive measure in health care workers and and those who are exposed to 
risk of HIV infection. Post exposure prophylaxis should be initiated as soon 
as possible within the first few hours and not later than 72hours of 
exposure.Two NRTI’S used for 4 weeks for less severe exposure and two 
NRTI’S plus other group of drugs.  
 
 
  
 
 
 
 
MONITORING THE EFFICACY OF ART : 
 Clinical improvement – gain in weight, decrease in occurrence  
& severity of HIV related infections 
 Increase in total lymphocyte count  
 Improvement in biological markers of HIV – CD4 count & RNA 
PREVENTIVE MEASURES IN HIV INFECTION : 
                 Health Education regarding safe sex practice,avoidance of IV drug 
abuse and tattooing is most important measure in preventing HIV 
transmission.All blood donors should be screened for HIV infection to 
prevent blood borne infections. 
                  Avoiding unnecessary injections and use of sterilised  disposable 
needle & syringes are also an effective measures in preventing HIV 
transmission. 
               Pregnant women with HIV infection should be advised to avoid 
pregnancy to reduce the mother to fetus transmission.  
                  
 
            
  
 
 
 
 
 CLASSIFICATION OF ANTI RETROVIRAL DRUGS 
NUCLEOSIDE OR NUCLEOTIDE REVERSE TRANSCRIPTASE 
INHIBITORS 
DRUGS DOSE COMMON SIDE EFFECTS 
ZIDOVUDINE 200mg tds or 
300 mg bd 
Anaemia, neutropenia, lactic 
acidosis, cardio toxicity 
DIDANOSINE 200mg bd Peripheral neuropathy, pancreatitis, 
hepatitis. 
ZALCITABINE 0.75mg tds Peripheral neuropathy, aphthous 
ulcers, hepatitis. 
STAVUDINE 40mg bd Peripheral neuropathy, pancreatitis, 
hepatitis. 
LAMIVUDINE 150mg bd Rash and peripheral neuropathy 
EMTRICITABINE 200 qid Skin discoloration and hepato 
toxicity. 
ABACAVIR 300 bd Rash, fever. 
TENOFOVIR 300 qid Gastrointestinal distress. Renal 
toxicity. 
 
  
 
 
 
 
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS 
DRUGS DOSE COMMON SIDE EFFECTS 
NEVIRAPINE 200mg  
od 
Skin rash, hepatotoxicity. 
DELAVIRIDINE 400 mg 
tds 
Skin rash, hepatotoxicity 
EFAVIRENZ 600 mg 
od 
Skin rash, neurological disturbances 
EDRAVIRINE 200 mg 
bd 
Skin rash. 
RILIPIVIRINE 25 mg 
qid 
 Dizzinesss,nausea,vomiting, neurological 
disturbances 
 
 
 
 
 
 
  
 
 
 
 
PROTEASE INHIBITORS 
DRUGS DOSE COMMON SIDE EFFECTS 
SAQUINAVIR 1000mg bd GI disturbances, dyslipidemia, PR and QT 
interval prolongation 
RITONAVIR 600 mg bd GI disturbances, dyslipidemia, hepatitis 
INDINAVIR 800 mg tds Dyslipidemia, renal stones. 
NELFINAVIR 750 mg tds GI disturbances, dyslipidemia, 
AMBRANAVIR 1200 mg bd GI disturbances, dyslipidemia, renal stones. 
LOPINAVIR 400mg 
/100mg bd 
GI disturbances, dyslipidemia, PR and QT 
interval prolongation 
ATAZANAVIR 400 mg qid GI disturbances, dyslipidemia, PR and QT 
interval prolongation, skin rash. 
TIPRANAVIR 500 mg bd GI disturbances, dyslipidemia, skin rash, 
hepatitis, intracranial hemorrhage 
DARUNAVIR 600 mg bd GI disturbances, dyslipidemia, skin rash, 
hepatitis. 
 
 
 
  
 
 
 
 
ENTRY INHIBITORS 
DRUGS DOSE COMMON SIDE EFFECTS 
ENFUVIRTIDE 90 mg sc 
bd 
Skin rash, local injection reaction, bacterial 
pneumonia 
MARAVIROC 150 to 600 
mg bd 
Hepatotoxicity, skin rash,  gastro intestinal 
disturbances, musculoskeletal symptoms. 
INTEGRASE INHIBITORS 
DRUGS DOSE COMMON SIDE EFFECTS 
RALTEGAVIR 400mg bd GI disturbances, muscle weakness, 
rhabdomyolysis. 
ELVITEGRAVIR Under 
trial 
Under trial. 
 
 
 
 
 
  
 
 
 
 
 CARDIOVASCULAR ABNORMALITIES IN HIV PATIENTS 
                         HIV infection is the one of the leading cause of acquired heart 
disease throught the world. Cardiovascular abnormalities are the most 
common cause of death in HIV patients Various heart diseases have been 
reported in approximately 40% of autopsy cases and during life by 
echocardiography in around 25% of patients with AIDS.Initially 
cardiomyopathy was the predominant cardiac complication,but after the 
introduction of  HAART coronary artery disease and other atherosclerotic 
vascular disease are becoming the the most common cardiac complication in 
HIV patients. But often these are underdiagnosed. 
                 HIV tends to persist in reservoir cells(dendritic cells) of 
myocardium and cerebral cortex even after antiretroviral therapy.These cells 
are playing a major role in development of pathogenesis of cardiac 
manifestations.   
                  Cardiac complications occur in late stage of the disease with  low  
CD4count .The most common cardiovascular complications in HIV patients 
include systolic and diastolic dysfunction,pericardial effusion and dilated 
cardiomyopathy. 
  
 
 
 
 
         Other less common complications include infective endocarditis, 
nonbacterial thrombotic endocarditis, pulmonary hypertension,vasculitis, 
accelerated atherosclerosis and coronary artery disease and arrhythmias . 
Various  mechanisms have been described in pathogenesis of cardiac 
complications in HIV patients. 
The possible mechanisms include 
1.AIDS related myocarditis 
               Reservoir cells(dendritic cells) in myocardium cause release of 
various cytokines in respose to HIV infection and leads to progressive tissue 
damage. 
2.Autoimmunity 
             Cardiac specific autoantibodies  have been reported in upto 30% of 
HIV related cardiac abnormalities.HIV has a direct effect on potentiating 
effect on leukocyte interaction with cardiovascular tissues leading to ECM 
degradation,myocyte hypertrophy and  replacement fibrosis.Antibodies to 
highly cardiac specific protein Beta myosin have been found  higher levels in 
HIV patients with myocardial disease than those without HIV infection. 
 
  
 
 
 
 
3.Nutritional  deficiencies  
                  Deficiencies of selenium,betacarotene,vitamin Bgroup A&E,zinc 
and magnesium have been implicated in pathogenesis. 
4.Drug toxicity  
                 Anti retroviral therapy NRTI’S and anticancer therapy doxorubicin  
used  for Kaposi sarcoma are most commonly associated with cardiotoxicity 
                Zidovudine causes diffuse destruction of cardiac mitochondrial 
structures and inhibition of mitochondrial DNA replication.Lactic acidosis 
due to  mitochondrial dysfunction also aggravates the myocardial 
dysfunction. 
5.Opportunistic infections 
             Infections have been implicated in pathogenesis of cardiac 
involvement in HIV infection include  Toxoplasmosis,Cryptococcosis, 
Cytomegalovirus, Candida spp, Pneumocytis carinii ,Microsporidium 
spp,Histoplasma capsulatum,atypical mycobacterium and aspergillus. 
 
 
 
 
 
  
 
 
 
 
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION 
                 HIV patients with left ventricular dysfunction can be 
asymptomatic or may present with features of heart failure .Patients with 
encephalopathy are more likely  to die of heart failure than those without 
encephalopathy .Myocarditis is the most important factor implicated in the 
pathogenesis of left ventricular dysfunction. 
       HIV infection increases the various cytokine release like TNF 
alpha which causes myocardial damage and dilated cardiomyopathy which is 
also an important cause of LV systolic dysfunction.Various opportunistic 
infections are also playing a major role in the pathogenesis of left ventricular 
dysfunction 
Nutritional deficiencies like selenium and vitamin B12 also associated 
with myocardial dysfunction.Levels of carnitine ,growth hormone and 
thyroid hormones are also altered in HIV infection which leads to LV 
dysfunction. 
         Echocardiography is used  in assessing the wall thickness 
,ejection fraction and fractional shortening .Diuretics,beta blockers and 
angiotensin converting enzyme (ACE) inhibitors are used in managing the 
patients with LV systolic dysfunction . 
 
  
 
 
 
 
DIASTOLIC DYSFUNCTION    
                 Left ventricular diastolic dysfunction seems to be a common 
cardiac disorder in HIV-infected patients and is often associated with 
myocardial hypertrophy.  
                  The pathogenesis of HIV associated diastolic dysfunction is likely 
multifactorial.First although it remains controversial, several studies suggest 
that hypertension is associated with antiretroviral use ,including prolonged 
duration of antiretroviral therapy and treatment with protease inhibitors .  
               HIV has a direct effect on cardiac myocytes and causes myocyte 
hypertrophy and replacement fibrosis which is the important factor in 
pathogenesis of diastolic dysfunction.Indivividual with HIV infection have 
high rates of inflammation which may predispose HIV patients to diastolic 
dysfunction. 
              Diastolic dysfunction  occurs due to noncompliance of ventricle.  
Most of patients with diastolic dysfunction present with exertional dyspnoea.   
              Diagnosis can be confirmed by Echocardiography.  Betablockers are 
the mainstay of treatment. 
 
  
 
 
 
 
DILATED CARDIOMYOPATHY 
                       Dilated cardiomyopathy was first described in HIV infection in 
1986. Incidence of dilated cardiomyopathy in  HIV infection is <8%.Most of 
them are asymptomatic or may present with signs of failure.The increasing 
occurrence of HIV associated cardiomyopathy detected by autopsy studies 
and by echocardiographic fidings strongly suggests that a careful cardiologic 
evaluation should be made to detect early involvement of the heart in HIV 
patients. Direct action of HIV on myocardial tissue or release of the 
proteolytic enzymes are an important causes of dilated cardiomyopathy. 
                 Various opportunistic infections ,Antiretroviral therapy like  
zidovudine and doxorubicin used in management of Kaposi sarcoma are 
related with cardiotoxicity and lead to development of dilated 
cardiomyopathy.Diagnosis of  dilated cardiomyopathy can be made by  ECG 
findings like nonspecific intraventricular conduction defects,RBBB 
&LBBB.Echocardiogarm is useful in assessing dilation of cardiac chambers 
,hypokinesia, and the LV ejection fraction .Diuretics,beta blockers 
,angiotensin converting enzyme (ACE) inhibitors and mineralocorticoid 
receptor antagonists are used in treating  the patients with dilated 
cardiomyopathy with heart failure. 
 
  
 
 
 
 
PERICARDIAL EFFUSION  
                   Incidence of pericardial effusion in HIV infection  is 11%. 
Aymptomatic pericardial effusions are more common and some times 
pericardial effusion itself is suggestive of HIV infection.So HIV infection  
should be suspected in young patients with pericardial effusion or 
tamponade.Clinically significant effusions are usually caused by bacterial or  
viral  or malignant disease.Unusual infections like nocardia,and herpes  
simplex infections  can also cause pericardial effusion in association with 
cytomegalo virus infection. 
                  Various mechanisms have been described in the pathogenesis  of 
pericardial effusion in  HIV infection. 
Possible mechanisms include  
1.Opportunistic infections 
2.Malignancies-kaposi sarcoma and lymphoma   
3.Capillary leak syndrome due to cytokine release 
         4.Uremic pericarditis due to HIV associated nephropathy 
              Usual manifestations of pericardial effusions include chest pain   and 
breathing difficulty. 
           If patient develops pericardial tamponade hypotension,muffled heart 
sounds and elevated jugular venous pulse will be present.This is also known 
as Beck’s traid. 
  
 
 
 
 
  Diagnosis  
          1.ECG-low voltage QRS complex    
  2.CXR PA view – cardiomegaly 
  3.Echocardiogarm-RA&RV collapse in pericardial tamponade 
          4.Pericardial fluid analysis-gram stain/culture/malignant cells 
                Spontaneous resolution occurs in 40% of case of pericardial 
effusion.Pericardiocentesis should be done if patient develops cardiac 
tamponade. 
INFECTIVE ENDOCARDITIS 
                   Incidence of infective endocarditis in HIV population is 6%.Most 
common bacterial infections causing infective endocarditis in HIV patients 
are staphylococcus and salmonella species.Other organisms include 
aspergillus and candida species 
                    Fulminant course of infective endocarditis occurs in late stages 
of disease in poorly nourished patients. Blood  culture   and echocardiogram 
are used in diagnosis of infectious endocarditis.IV antibiotics are according to 
culture&sensitivity are used in management. 
Operative indications  
            1.Hemodynamically stable patients 
            2.Blood culture positivity after appropriate IV antibiotics.  
            3.Severe valvular deformity 
  
 
 
 
 
CARDIOVASCULAR MALIGNANCIES 
                   Cardiovascular malignancies in HIV infection are usually 
metastatic diasease and occurs in advanced diaease.Kaposi sarcoma occurs in 
35% of AIDS patients.It is also known as angiosarcoma.Human herpes virus 
8 (HHV8) is the causative organism of Kaposi sarcoma.It occurs most 
commonly in homosexuals.Kaposi sarcoma is an endothelial neoplasm with a 
predilection  in the heart for subpericardial fat around the coronary 
arteries.Symptomps are due to pericardial effusion associated with epicardial 
location of the tumour.Pericadial fluid in Kaposi sarcoma is typically 
serosanguinous without infection or malignant cells. 
PRIMARY CARDIAC MALIGNANCY 
                       Primary cardiac malignancy in HIV patients is generally 
caused by cardiac lymphoma .Non Hodgkin lymphomas are 25 to 60 times 
more common in HIV patients.Cardiac lymphomas are the first manifestation 
of AIDS in 4% of patients.Cardiac lymphomas are associated with rapid 
progression of tamponade.Pericardial fluid analysis shows malignant cells but 
can be histologically normal.Although systemic chemotherapy with or 
without radiotherapy is beneficial, prognosis is poor 
 
 
  
 
 
 
 
ACCELERATED   ATHEROSCLEROSIS    AND    CORONARY  
ARTERY   DISEASE  
                     Human immunodeficiency virus infection may independently 
predispose to AMI(acute myocardial infarction) via combination of 
endothelial dysfunction,a heightened pro-inflammatory state,dyslipidemia 
and thrombosis. 
              Similarly,protease inhibitor therapy has the potential to induce an 
adverse metabolic phenotype that involves a similar pathogenic response that 
increase the risk of AMI particular during prolonged treatment. 
            The exact pathogenic role of HIV independent of associated 
modifiable and nonmodifiable risk factors is difficult to determine but may be 
important as a contributory factor in an already vulnerable patient.  
                HIV associated lipodystrophy is serious complication and patients 
with this syndrome are more prone to develop coronary artery disease and 
early recognition and treatment is effective measure in preventing coronary 
artery disease in patients with HIV  infection.Chances of restenosis are also  
high  after PCI because of accelerated atherosclerosis in HIV patients. 
 
 
 
 
  
 
 
 
 
PULMONARY HYPERTENSION  
               Incidence of pulmonary hypertension in HIV infection is 
0.5%.Cause of pulmonary hypertension in HIV infection is multifactorial and 
poorly understood.Genetic factors such as increased frequency of HLA-
DR6& DR52 and activation of alpha receptors have also been implicated in 
the pathogenesis of HIV associated pulmonary hypertension. 
              Left ventricular dysfunction due to global left ventricular dilation 
can result in  mitral valve regurgitation which leads to development of 
secondary pulmonary hypertension. 
SYSTEMIC HYPERTENSION(SHT) 
         Incidence of Systemic hypertension  before initiation was 20 to 
25%.But after the introduction of ART incidence have been increased 
because of metabolic complications related with protease inhibitors.Posssible 
mechanisms include HIV induced vasculitis, endothelial dysfunction and 
atheromatous  changes due to Antiretro viral therapy. 
 RHYTHM DISORDERS&AUTUNOMIC DYSFUNCTION 
               Rhythm disturbances and sudden cardiac death are common in HIV 
infection and account for 20% of cardiac related deaths in HIV 
  
 
 
 
 
infection.These rhythm disturbance are due to drugs like pentamidine and 
ganciclovir or associated electrolyte disturbances.   
INDICATIONS FOR ECHOCARDIOGRAPHIC ASSEESSMENT OF HIV 
POSITIVE PATIENTS. 
           1.Possible baseline assessment at the time of diagnosis 
           2.Clinical manifestion of possible cardiac involvement 
 Unexplained dyspnea,Pedal edema 
 Raised JVP,Third & Fourth heart sound 
 Cardiomegaly in Chest X-RAY 
           3.Viral infections  
 Cytomegalo Virus,Epstein barr virus, 
 Coxsackie virus,Adenovirus 
            4.History of Pre existing heart diseases  
 LV systolic dysfunction due to all cause 
 Valvular heart hisease 
 Suspicion of infective endocarditis in i.v drug abusers 
 
  
 
 
 
 
  5.High Risk HIV Patients with  
 Wasting,encephalopathy,CD4count <100/AIDS 
 Potentially cardiotoxic medication 
 Multiple Hospitalizations 
  6.Possible Monitoring every 1-2 years of asymptomatic HIV positive 
patients 
  7.Frequent assessment of HIV Positive Patients with Cardiovascular 
involvement           
                
 
 
 
 
 
 
   
  
 
 
 
 
      CARDIOVASCULAR  COMPLICATIONS  OF DRUGS 
     USED  IN  HIV INFECTION 
 
 CLASS DRUGS SIDE EFFECTS  
NRTI’S Abacavir,tenofovir 
zidovudine,lamivudine,di
danosine,zalcitabine 
Lactic acidosis, 
hypotension,cardiomyopathy 
NNRTI’S Delaviridine,  efavirenz, 
nevirapine 
Myocardial ischemia,arrhythmias 
Antibiotics Erythromycin,clarithrom
ycin, 
trimethoprim/sulfametho
xazole,rifampicin  
Orthostatic hypotension,QT 
prolongation and Ventricular 
tachycardias 
Antifungals AmphotricinB 
ketoconazole,itraconazole 
 
 
Hypertension,cardiomyopathy, 
Arrhythmias 
  
 
 
 
 
Antiviral agents Foscarnet,ganciclovir Reversible heart failure,ventricular 
tachycardias,hypotension 
Antiparasitic 
agents 
Pentamidine Hypotension,ventricular 
arrhythmias 
Chemotherapy 
agents 
Vincristine,doxorubicin Myocardial infarction ventricular 
arrhythmias,cardiomyopathy 
 
 
 
 
 
 
 
 
 
                    
  
 
 
 
 
                MATERIALS AND METHODS 
 
PARTICIPANTS 
  200 HIV positive  patients >12years of age coming to ART 
centre,Govt.Rajaji Hospital, Madurai. 
 
 STUDY POPULATION :  
               This study was conducted among 200 HIV positive patients coming 
to ART centre, Govt.Rajaji Hospital, Madurai. CD4 count, ECG and 
Echocardiograrm were done in all the participants of the study. Cases  were  
classified  as HIV patients into four groups  depending upon the CD4 cell 
count >500 stage1),CD4 cell count 200 – 500 (stage 2), and  50-200(stage 3) 
and <50 stage 4. 
Inclusion criteria 
 
• Age >12 yrs 
• Newly diagnosed HIV patients  
• Patients on ART therapy  
 
 
  
 
 
 
 
Exclusion criteria: 
    Patients with  
 Valvular heart disease. 
 Coronary artery disease. 
 Congenital heart disease 
 Rheumatic heart disease 
 Thyroid disorders  
 Pregnant women  
 
 
DATA COLLECTION:  
                  A detailed history with detailed clinical examination  was  done 
for the HIV positive individuals. The  blood samples of people belonging to 
study groups were  tested  for CD4 cell count. ECG and echocardiogram were 
done in study group. 
LABORATORY INVESTIGATIONS 
                                Blood samples were collected from the study group  and 
CD4 counts were obtained by flow cytometry.  Here the cells were 
conjugated to monoclonal antibodies against CD3 and CD4 cell surface 
markers. These cells were then made to pass through a flow chamber and 
subjected to intersection by a LASER beam. The flourescent signals obtained 
from the LASER beam intersecting the cells were analysed and  data 
  
 
 
 
 
obtained helped delineate the different cell sub populations based on their 
cluster differentiation.12 lead ECG and Echocardiogram were done in study 
group. 
DATA ANALYSIS  
                     The final data was entered onto Microsoft excel sheet 2007 
version and statistical analysis was done using SPSS software and chi – 
square test. The results were considered  very significant with p value < 0.01 
and significant with  p value <0.05. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 STUDY PROTOCOL: 
 All cases were classified into 3 categories based on CD4 cell count  
 12 lead ECG and Echocardiogram were done in study group. 
Design of study: 
  Prospective analytical  study 
Period of study: 
  5months (APRIL 2014 TO AUGUST2014) 
Collaborating departments: 
 Department of Medicine,  
 Department of Cardiology   
 Regional ART centre 
Ethical clearance  :Obtained 
Consent   :Individual written and informed consent. 
Analysis   :Statistical analysis-chi square test  
Conflict of interest : NIL 
Financial support  : NIL 
  
  
 
 
 
 
                  OBSERVATION AND RESULTS 
                                    Table 1 
 Age distribution of the study population (n=200) 
AGE GROUP FREQUENCY PERCENTAGE 
12-20 6 3% 
21-30 48 24% 
31-40 60 30% 
41-50 56 28% 
51-60 28 14% 
61-70 2 1% 
TOTAL 200 100% 
 
Comments: About 54% of study population were in the age group of 21-40 
years and 42% of study populalation  were in the age group of 41-60 years  
 
 
 
  
 
 
 
 
 
 
            Chart1:Age distribution in the study population 
 
   
 Comment: Most of study population were in the age group of 21 to 50years 
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                                Table 2 
 Gender distribution in the study population(n=200) 
GENDER  FREQUENCY  PERCENTAGE 
MALE 109 54.5% 
FEMALE 91 45.5% 
TOTAL 200 100% 
 
Comments: Males and females were almost equal in the study population  
 
 
 
 
 
 
 
                              
  
 
 
 
 
                             Table3 
Distribution of the study  population  according to ART status(n=200) 
ART STATUS FREQUENCY PERCENT 
ON ART 160 80% 
NEWLY 
DIAGNOSED 
40 20% 
TOTAL 200 100% 
 
Comment:Most of the study population were on ART. 
 
 
 
 
 
 
                                     
  
 
 
 
 
                                   Table4  
Staging of CD4 count in the study population(n=200)  
CD4 C0UNT  FREQUENCY PERCENT 
STAGE 1:  >500 60 30% 
STAGE 2: 200-500 54 27% 
STAGE 3: 50-200 46 23% 
STAGE 4: <50 40 20% 
TOTAL  200 100% 
 
Comments: About 57% of population  in the study group were stage 1& 2  
and about 43% of population  in the study group were  stage 3 & 4. 
 
 
 
 
  
 
 
 
 
     
               Chart2:CD4 count staging in the study population 
      
         
Comments: About 57% of the study population  were  in stage 1&2 and 43% 
of study population in stage 3&4 . 
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                            Table 5  
Prevalence of ECG abnormalities in the study population (n=200) 
ECG 
ABNORMALITIES  
FREQUENCY PERCENTAGE 
PRESENT  58 29% 
ABSENT 142 71% 
TOTAL  200 100 
ECG abnormalities in the study population  
ECG 
ABNORMALITIES 
FREQUENCY PERCENTAGE 
Poor progression of  R 
wave  
26 13% 
Low voltage QRS  18 9% 
RBBB 10 5% 
LBBB 4 2% 
TOTAL  58 29% 
 
Comments:ECG abnormalities were present in 29% of the study population 
ant most common finding was poor progression of R wave. 
 
  
 
 
 
 
 
Chart3:Prevalence of ECG abnormalities in study population (n=200) 
 
 
Comments : ECG abnormalities were present in about 29% of study 
population . 
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                            Table6 
 Prevalence of pericardial effusion  in the study population(n=200)  
 PERICARDIAL 
EFFUSION   
FREQUENCY  PERCENTAGE 
PRESENT 30 15% 
ABSENT 170 85% 
TOTAL 200 100% 
 
Comments: Pericardial effusion was present in around 15% of study 
population.P value is <0.001 signnificant . 
 
 
 
 
 
 
 
  
 
 
 
 
 
      Chart4:CD4 count staging and pericardial effusion  in the study group 
 
 
P value;<0.012 significant 
Comments: The difference in proportions of pericardial effusion in  stage 
1&2 and stage 3&4 is statistically significant and prevalence of pericardial 
effusion showed a close association with decreasing CD4 count. 
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                                Table 7  
Prevalence of systolic dysfunction in the study group(n=200) 
SYSTOLIC 
DYSFUNCTION 
FREQUENCY PERCENTAGE 
PRESENT  26 13% 
ABSENT 174 87% 
TOTAL 200 100% 
 
Comment: Systolic dysfunction was present in around 13% of study 
population.P value is <0.001 significant. 
 
 
 
 
 
 
  
 
 
 
 
Chart5:CD4 count staging and systolic dysfunction in the study group(n=200) 
 
 
 
P value <0.018 significant. Comments:The difference in proportions of  
systolic dysfunction in stage 1&2 and stage 3&4 is statistically significant 
and prevalence of systolic dysfunction showed a close association with 
decreasing CD4 count. 
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    Table 8  
Prevalence of diastolic dysfunction in the study population(n=200) 
DIASTOLIC 
DYSFUNCTION 
FREQUENCY PERCENTAGE 
PRESENT  23 11.5% 
ABSENT 187 88.5% 
TOTAL  200 100% 
 
Comment: Diastolic dysfunction was  present in around 11.5% of study 
population.P value is <0.001 significant 
 
 
 
 
  
 
 
 
 
 
 
  
Chart6:CD4 count staging and diastolic dysfunction  in the study 
group(n=200) 
 
 
 
P value <0.046significant 
Comments: The difference in proportions of diastolic dysfunction in stage 
1&2 and stage 3&4 is statistically significant and prevalence of diastolic 
dysfunction showed a close association with decreasing CD4 count 
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                                           Table 9  
Prevalence of dilated cardiomyopathy in  the study population (n=200) 
DCM FREQUENCY PERCENTAGE 
PRESENT 18 9% 
ABSENT 182 91% 
TOTAL 200 100% 
 
Comment:Dilated cardiomyopathy was  present in around 9% of study 
population.P value is <0.001 significant 
 
 
 
 
 
 
  
 
 
 
 
 
 
Chart 7:Prevalence of dilated cardiomyopathy in the study population  
 
 
P value <0.023 significant 
Comments: The difference in proportions of dilated cardiomyopathy  in stage 
1&2 and stage 3&4 is statistically significant and prevalence of dilated  
cardiomyopathy showed a close association with decreasing CD4 count  
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                                 Table10  
 Prevalence of other abnormalities in the study population(n=200) 
OTHER ABNORMALITIES FREQUENCY  PERCENTAGE 
RWMA 3 1.5% 
INFECTIVE ENDOCARDITIS 1 O.5% 
PULMONARY HYPERTENSION  4 2% 
TOTAL  8 4% 
 
Comments:Prevalence of other cardiac abnormalities were present in 4% of  
the study population  
 
 
 
 
 
  
 
 
 
 
                                                  Table 11 
 Correlation of various cardiac abnormalities and CD4 count  
Cardiac 
abnormalities  
stage1 stage 2 stage 3 Stage4 Total P 
value 
Pericardial 
effusion  
2 4 10 14 30 0.012 
Systolic 
dysfunction  
2 3 9 12 26 0.018 
Diastolic 
dysfunction  
1 4 8 10 23 0.046 
Dilated 
cardiomyopathy 
1 3 6 8 18 0.023 
RWMA  0 1 1 1 3 0.453 
Infective 
endocarditis  
0 0 1 0 1 0.665 
Pulmonary 
hypertension  
1 2 1 0 4 0.836 
                                   
  
 
 
 
 
 COMMENTS:  
 All the cardiac abnormalities were prevalent in stage 3&4 and 
the p value is significant  
 There was a statistically significant positive linear correlation 
between the CD4 count and cardiac abnormalities.i.e 
decrease in CD4 count had a corresponding increasing cardiac 
abnormalities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Chart 8:Prevalence of cardiac abnormalities in the study population 
 
 
 
                             
Comments:Pericardial effusion was  the most common abnormality seen in 
the study population and all the abnormalities had  statistically significant p 
value <0.001 
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                                      DISCUSSION  
                Cardiovascular abnormalities are more common in HIV infection in 
late stages of disease .This study was conducted in 200 HIV patients 
including newly diagnosed and patients on ART attending ART 
clinic,Government Rajaji Hospital,Madurai.The study population were 
divided into 4 groups according to CD4 count.About 54% of study 
population were in the age group of 21-40 years and 42% of study 
populalation  were in the age group of 41-60 years. 
                Around 70% of study population were on ART and 30% of  the  
study population were newly diagnosed.Gender distribution  were  also 
almost equal in the study group.ECG and Echocardiography were performed 
in the study population. 
              In this study  most of the patients with HIV infection had 
echocardiac abnormalities  which were clinically quiescent.This suggests that 
echocardiographic screening is important tool for diagnosing subclinical 
cardiac abnormalities.  
               Pericardial effusion was the most commonly  observed finding in 
HIV patients.It was seen in around 15% of cases and among that most of the 
cases were in stage 3&4(CD4 count<200)  with the spectrum ranging from 
asymptomatic mild effusion to massive pericardial effusion.  
  
 
 
 
 
              Pericardial effusion is the most common  cardiac problem associated 
with shortened survival . Causes of pericardial effusion in HIV infection 
include tuberculosis,secondary infections ,malignancy and part  of 
generalised effusive process. Echocardiography is the diagnostic  procedure 
and  pericardiocentesis is needed in symptomatic patients. 
        Systolic dysfunction was present in 13% of patients with the p value 
<0.001.Most of patients were aymptomatic and had mild LV systolic 
dysfunction and were in stage 3&4.Only few patients were asymptomatic. 
Systolic dysfunction is an important cause of morbidity and mortality and 
symptomatic heart failure occur in 6% patients with advanced illness. Causes 
include  myocarditis ,dilated cardiomyopathy and coronary artery disease.   
              Diastolic dysfunction was also most commonly observed finding in 
this study.It was seen in 12% of patients with p value<0.001and majority of 
the patients had were in stage 3&4 and most of the patients had exertional 
dyspnea.Diastolic dysfunction is due to ventricular filling abnormalities due 
to noncompliance of the ventricle. 
           Dilated cardiomyopathy (DCM)  was found in 9% of the patients in 
the study group with the p value <0.001and most of the cases were in stage 
3&4. 
  
 
 
 
 
           Most  common causes of  DCM in HIV infection include 
myocarditis,opportunistic infections,nutritional and drug induced especially 
zidovudine. 
           Other cardiac  abnormalities  seen in the study group were regional 
wall motion abnormality (RWMA),infective endocarditis (IE) and pulmonary 
hypertension (PHT) which were statistically not significant. From this study 
we  conclude  that all cardiac abnormalities occur in late stage of HIV 
patients with low  CD4 count .As the CD 4 count decreases cardiovascular 
abnormalities increases.So echocardiographic screening is mandatory in HIV 
patients with CD4 count<500/micrlitre.  
              Eventhough decrease in  CD4 count well correlates with  the  cardiac 
abnormalities,this study had some limitations.Because there may be some 
confounding factors like smoking ,alcohol  and  substance abuse ,diabetes 
mellitus,hypertension and dyslipidemia  which can also  cause these cardiac 
manifestations. 
            Although the  exact mechanism of  the pathogenesis of cardiovascular 
abnormalities in  HIV  is  multifactorial  and poorly understood,progression 
of cardiac problems in HIV infection can be reduced  by effective 
antiretroviral therapy . 
                 
  
 
 
 
 
                                        SUMMARY 
                  HIV infection is most oftenly  associated with cardiac 
abnormalities.This study was conducted in 200 HIV patients including newly 
diagnosed and patients on ART and the study population were divided into 4 
groups according to CD4 count.About 54% of study population were in the 
age group of 21-40 years and 42% of study populalation  were in the age 
group of 41-60 years. 
                 Around 70% of study population were on ART and 30% of study 
population were newly diagnosed.Gender distribution were also almost equal 
in the study group.ECG and Echocardiography were performed in the study 
population. 
                Systolic dysfunction(13%) and diastolic dysfunction(12%) 
pericardial effusion(PE) (15%)  and dilated cardiomyopathy(DCM)(9%)  
were most prevalent in the study group and the p value was 
<0.001,statistically significant and were seen most commonly in HIV patients 
receiving antiretroviral therapy  
                Other abnormalities  like  infective endocarditis(IE), regional wall 
motion abmormality(RWMA) and pulmonary hypertension(PHT) were seen 
in only few patients which were statistically not significant.  
                       
  
 
 
 
 
           These cardiac abnormalities were more prevalent in stage 3 and 4 with 
CD4 count <200/microlitre.There is a positive linear correlation between 
prevalence of Systolic and diastolic dysfunction, pericardial effusion(PE) and 
dilated cardiomyopathy(DCM) with a fall in the CD4 count 
 
                                        
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
                                   CONCLUSION  
         Cardiovascular  abnormalities  are  more common and predictable       
complications in  late stages  of HIV infection.This study was done. 
 To highlight  the various cardiovascular abnormalities occurring in HIV 
infection.  
 Many of these abnormalities are associated with increased morbidity and 
mortality . 
 Pericardial effusion ,systolic and diastoloic dysfunction,and dilated 
cardiomyopathy are the most common cardiac abnormalities occurring 
in significant number of  HIV patients with low CD4 count. So these 
parameters can also be used as predictors of disease progression. 
 So all HIV patients with low CD4 count(<200/microlitre) should be 
screened for cardiac abnormalities.Early diagnosis and management of  
these complications is associated with increased survival rates and 
clinical outcomes in HIV patients . 
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                               PROFORMA  
Name:                      Age / Sex:    Occupation: 
Presenting complaints: 
 H/o chest pain, H/o palpitation, H/o breathing difficulty, H/o pedal 
edema, H/o syncope,  
Past History: 
H/o DM,HT,CKD,CVD, Drug intake, CAD, Thyroid disorders  
Clinical Examination: 
General Examination: 
 Consciousness, pallor, jaundice,cyanosis, clubbing,pedal 
edema,lymphadenopathy 
Vitals:  Pulse Rate:   Blood Pressure:  Respiratory Rate:   
Systemic examination: CVS:                         RS:    
                                       ABDOMEN:       CNS: 
Laboratory investigations: 
 CD4 count,ECG&Echocardiogram                    
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1 51/m 678 - - - - - - - - 
2 19/f 1720 - - - - - - - - 
3     3 21/m 518 - - - + - - - 
4 51/m 548 + - - - - - - - 
5 42/f 1047 - - - - - - - - 
6 18/f 910 - - - - - - - - 
7 21/f 1200 + - - - - - - - 
8 53/m 612 - - + - - - - - 
9 20/f 42 + - - + - - - - 
10 38/f 527 - - - - - - - - 
11 58/f 57 - + - - - - - - 
12 30/f 214 + - - - - - - + 
13 54/m 647 + - - - - - - - 
14 20/m 85 - + -   - - - - 
15 24/m 1590 - - - - - - - - 
16 21/f 77 + - - - - - - - 
17 37/f 98 - - - - - - - - 
  
 
 
 
 
18 23/f 612 - - - - - - - - 
19 53/f 36 + - + - - - - - 
20 54/f 148 - - - - - - - - 
21 45/m 749 - - - - - - - - 
22 53/f 160 - + - - - - - - 
23 36/f 890 + - - - - - - - 
24 54/m 40 - - + - - - - - 
25 59/m 114 + - - - - - - - 
26 36/m 102 - - - - - - - - 
27 55/m 396 - - - - - - - - 
28 25/m 26 - - - - - - - - 
29 47/f 368 + - - + - - - - 
30 56/m 103 - - - - - - - + 
31 23/f 32 - - - - - - - - 
32 56/m 690 + - - - - - - - 
33 26/m 37 + - - - - - - - 
34 37/m 707 - - - - - + - - 
35 39/f 848 - - - - - - - - 
36 21/m 59 - - - - - - - - 
37 35/f 480 - - - - - - - - 
38 57/m 960 - - - - - - - - 
39 40/m 414 + + - - - - - - 
  
 
 
 
 
40 43/m 710 - - - - - - - - 
41 36/m 998 - - - - - - - - 
42 39/m 108 - - - - - - - - 
43 54/f 414 + - - - - - - - 
44 23/f 319 - - - - + - - - 
45 38/m 26 - - - - - - - - 
46 34/m 112 - - - - - - - - 
47 45/m 714 - - - - - - - - 
48 40/f 28 - - - - - - - - 
49 46/f 122 + + - - - - - - 
50 39/m 41 - - - + - - - - 
51 17/f 29 - - - - - - - - 
52 24/f 142 + - - - - - - - 
53 57/f 69 + - - - - - - - 
54 40/m 804 - - - - - - - - 
55 33/m 40 - - - + - - - - 
56 40/f 109 - + - - - - - - 
57 26/f 78 - - - - - - - - 
58 42/f 312 + - - - - - - - 
59 38/m 39 - - - + - - - - 
60 24/m 314 + - - - - - - - 
61 45/m 647 - + -  - - - - - 
  
 
 
 
 
62 39/m 298 - - -  - - - - - 
63 56/m 947 + - -  - - - - + 
64 32/f 418 - - - + - - - - 
65 56/m 22 - - +  - - - - - 
66 33/m 936 - - -  - - - - - 
67 38/m 29 - - -  - - - - - 
68 61/m 290 - - -  - + - - - 
69 57/f 712 - - -  - - - - - 
70 58/f 110 - + - - - - - - 
71 51/m 777 - - - - - - - - 
72 33/f 78 - - - - - - - - 
73 56/f 92 - - - - - - + - 
74 40/f 38 - - + - - - - - 
75 25/f 128 - - - - - - - - 
76 37/f 814 + + - - - - - - 
77 22/f 1812 - - - - - - - - 
78 27/m 43 - - - - - - - - 
79 57/m 137 - - - - - - - - 
80 50/f 113 + - - - + - - - 
81 51/f 24 - - - - - - - - 
82 35/f 1047 - - + - - - - - 
83 36/m 129 - - - - - - - - 
  
 
 
 
 
84 59/f 35 + - - + - - - - 
85 30/f 629 + - - - - - - - 
86 37/m 147 - + - - - - - - 
87 60/m 110 - - - - - + - - 
88 35/m 25 - - + - - - - - 
89 51/m 639 - - - - - - - - 
90 36/f 117 - - - - - - - - 
91 29/m 818 - - - - - - - - 
92 27/f 268 - - - + - - - - 
93 26/m 276 + - - - - - - - 
94 60/m 854 - - - - - - - - 
95 32/m 32 - - - - - - - - 
96 52/m 400 - - - + - - - - 
97 35/m 408 - - - + - - - - 
98 31/m 719 - - - - - - - - 
99 27m/ 49 - - - - - - - - 
100 50/m 153 - - - - - - - - 
101 31/f 675 - - - - - - - - 
102 34/m 1032 - - - - - - - - 
103 40/m 245 - - - - - - - - 
104 26/m 57 - - - - - - - - 
105 42/f 178 - - - - - - - - 
  
 
 
 
 
106 32/m 891 - - - - - - - - 
107 46/m 234 + - - - - - - - 
108 28/m 1126 - - - - - - - - 
109 48/f 897 - - - - - - - - 
110 53/m 675 - - - - - - - - 
111 35/m 648 - - - - + - - - 
112 33/m 486 - - - + - - - - 
113 27/f 68 + - - + + - - - 
114 55/m 701 - - - + - - - - 
115 19/m 28 - - - + - - - - 
116 33/f 32 + - - - - - - - 
117 54/m 80 - - + - + - - - 
118 27/m 240 - - - - - - - - 
119 62/m 100 - - - - - - - - 
120 56/f 40 - - + - - - - - 
121 32/m 316 - - - - - - - - 
122 42/m 23 - + - - - - - - 
123 47/m 260 - + - - - - - - 
124 34/f 196 - - - - - - - - 
125 31/f 114 + - + - + - - - 
126 47/f 512 - - - - - - - - 
127 27/m 209 - - - - - - - - 
  
 
 
 
 
128 26/m 72 - + - - - - - - 
129 48/f 419 - - + - - - - - 
130 45/f 227 - - - + - - - - 
131 37/m 1314 - - - - - - - - 
132 40/f 454 - - - - - - - - 
133 35/f 69 + - - - - - - - 
134 39/f 1012 + - - - - - - - 
135 28/f 34 - - + - - - - - 
136 57/m 139 - - + - - - - - 
137 41/f 39 - - - - - - - - 
138 36/f 406 + - + - - - - - 
139 27/f 1678 - - - - - - - - 
140 39/m 476 - - - + - - - - 
141 58/f 49 - - + - - - - - 
142 37/m 39 - - - - - - - - 
143 30/f 898 - - - - - - - - 
144 42/m 496 - - - - - - - - 
145 37/f 308 - - - - - - + - 
146 40/m 1012 - - - - - - - - 
147 29/m 61 - - - - - - - - 
148 38/m 176 + - - - + - - - 
149 36/m 35 - - + - - - - - 
  
 
 
 
 
150 50/m 650 + - + - + - - - 
151 30/f 30 - - + - - - - - 
152 27/f 300 + - - - - - - - 
153 54/m 26 - + - - - - - - 
154 37/m 34 - - - - - - - - 
155 28/f 728 - - - - - - - - 
156 46/f 1509 - - - - - - - - 
157 28/m 94 - - - - - - - - 
158 43/m 41 + - - + - - - - 
159 36/f 59 - - - - - - - - 
160 34/m 1065 - - - - - - - - 
161 46/f 897 + - - - - - - - 
162 29/m 219 - + - - - - - - 
163 39/m 46 - - + - - - - - 
164 45/f 38 - - - - - - - - 
165 35/f 244 + - - - - - - - 
166 22/m 92 - - - - - - - - 
167 59/f 560 - - - - - - - - 
168 40/f 24 - - + - - - - - 
169 27/m 77 - + - - - - -- - 
170 39/f 949 - - - - - - -- - 
  
 
 
 
 
171 45/m 249 - - - - - - - + 
172 47/f 369 - - - - - - - - 
173 34/f 75 - - + - - - - - 
174 40/m 340 - - - + - - - - 
175 28/m 481 - - + - - - - - 
176 22/f 68 + - - - - - - - 
177 34/m 1412 - - - - - - - - 
178 43/m 380 - - - - - - - - 
179 25/m 679 - + - - - - - - 
180 42/f 1208 - + - - - - - - 
181 39/f 194 + - + - + - - - 
182 33/f 838 - - - - - - - - 
183 29/m 146 - - + - - - - - 
184 37/m 914 - - - - - - - - 
185 22/f 1844 - - - - - - - - 
186 60/f 184 + - - - + - - - 
187 28/f 1345 - - - - - - - - 
188 51/m 612 - - - - - - - - 
189 25/f 124 - - - - - - - - 
190 52/m 568 - - - - - - - - 
191 38/m 26 - - + - + - - - 
192 32/m 517 - - - - - - - - 
  
 
 
 
 
193 56/m 49 - + - - - - - - 
194 53/f 678 - - - - - - - - 
195 34/m 890 + - - - - - - - 
196 31/f 1149 - - - - - - - - 
197 54/m 197 - - - - - - - + 
198 22/f 80 - + - - - - - - 
199 25/m 982 - - - - - - - - 
200 55/m 1119 - - - - - - - - 
 
 
 
 
 
 
     
  
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
  
  
  
